From bench to bedside: what physicians need to know about endothelial progenitor cells

Am J Med. 2011 Jun;124(6):489-97. doi: 10.1016/j.amjmed.2011.01.015.


Since the discovery of endothelial progenitor cells in 1997, the scientific world has seen their ups and downs. There has been much discussion about the detection methods of endothelial progenitor cells and their diagnostic and predictive value. A lack of standardized methods to define endothelial progenitor cells has led to a number of nomenclatures and measuring methods that are difficult for clinicians to oversee. Therefore, only specialized hematologists and cardiologists were aware of their existence. Now it is time for a change: Most of the controversies have been eliminated by elaborate studies. This review aims to give an overview to the clinically working physician about the measurement, diagnostic potential, predictive value, and therapeutic potential of endothelial progenitor cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies
  • Cardiovascular Diseases / diagnosis*
  • Cardiovascular Diseases / pathology
  • Cardiovascular Diseases / therapy
  • Cell Proliferation
  • Chemokine CXCL12 / analysis
  • Endothelial Cells*
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / pathology*
  • Exercise
  • Flow Cytometry
  • Hematopoietic Stem Cells*
  • Humans
  • Neovascularization, Pathologic
  • Neovascularization, Physiologic
  • Predictive Value of Tests
  • Risk Factors
  • Smoking / adverse effects
  • Stem Cell Transplantation* / trends


  • Antibodies
  • Chemokine CXCL12